• Legislation1 on orphan medicinal products, eagerly awaited by patients suffering from rare diseases for many years, came into force in the European Union in April 2000. • ‘ Orphan’ medicinal products are for treating conditions that occur so rarely that sponsors are unwilling to develop them under normal market conditions.